Ocumension Therapeutics Management

Management criteria checks 2/4

Ocumension Therapeutics' CEO is Victor Liu, appointed in Aug 2018, has a tenure of 6.25 years. total yearly compensation is CN¥5.94M, comprised of 71.5% salary and 28.5% bonuses, including company stock and options. directly owns 4.15% of the company’s shares, worth HK$175.95M. The average tenure of the management team and the board of directors is 3.8 years and 5 years respectively.

Key information

Victor Liu

Chief executive officer

CN¥5.9m

Total compensation

CEO salary percentage71.5%
CEO tenure6.3yrs
CEO ownership4.1%
Management average tenure3.8yrs
Board average tenure5yrs

Recent management updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Jun 13
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Recent updates

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Sep 21
With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Aug 15
Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Jun 13
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Apr 29
Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Mar 14
Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

Aug 29
Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Jul 13
We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

Jun 02
Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Jan 20
We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Sep 27
We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

Jan 23
Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

CEO Compensation Analysis

How has Victor Liu's remuneration changed compared to Ocumension Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥323m

Mar 31 2024n/an/a

-CN¥351m

Dec 31 2023CN¥6mCN¥4m

-CN¥380m

Sep 30 2023n/an/a

-CN¥399m

Jun 30 2023n/an/a

-CN¥418m

Mar 31 2023n/an/a

-CN¥411m

Dec 31 2022CN¥5mCN¥3m

-CN¥403m

Sep 30 2022n/an/a

-CN¥393m

Jun 30 2022n/an/a

-CN¥383m

Mar 31 2022n/an/a

-CN¥322m

Dec 31 2021CN¥5mCN¥4m

-CN¥260m

Compensation vs Market: Victor's total compensation ($USD820.24K) is above average for companies of similar size in the Hong Kong market ($USD392.59K).

Compensation vs Earnings: Victor's compensation has increased whilst the company is unprofitable.


CEO

Victor Liu (53 yo)

6.3yrs

Tenure

CN¥5,943,000

Compensation

Mr. Ye Liu, also known as Victor, serves as Chief Executive Officer at Ocumension Therapeutics since joining on August 1, 2018 and has been its Executive Director since November 23, 2018. Mr. Liu is respon...


Leadership Team

NamePositionTenureCompensationOwnership
Ye Liu
CEO & Executive Director6.3yrsCN¥5.94m4.15%
HK$ 176.0m
Zhaopeng Hu
Chief Development Officer & Executive Director4.4yrsCN¥2.21m0.46%
HK$ 19.5m
Tim Ruan
CFO & Joint Company Secretary1.8yrsno datano data
DongHong Chen
Chief Medical Officer5.1yrsno datano data
Qinglei Zuo
Chief Commercial Officer3.8yrsno datano data
NA NA
Chief Medical Officerless than a yearno datano data
Tingchan Chen
Joint Company Secretary1.2yrsno datano data

3.8yrs

Average Tenure

45.5yo

Average Age

Experienced Management: 1477's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ye Liu
CEO & Executive Director6yrsCN¥5.94m4.15%
HK$ 176.0m
Zhaopeng Hu
Chief Development Officer & Executive Director4.6yrsCN¥2.21m0.46%
HK$ 19.5m
Yanling Cao
Non-Executive Director5.4yrsno datano data
Ting Yuk Wu
Independent Non-Executive Director4.4yrsCN¥720.00kno data
Lian Yong Chen
Non-Executive Chairman of the Board6.5yrsno data10.81%
HK$ 458.5m
Zhenyu Zhang
Independent Non-Executive Director2.6yrsCN¥135.00kno data
Yiran Huang
Independent Non-Executive Director4.4yrsCN¥180.00kno data
Wei Li
Non-Executive Director6.6yrsno datano data

5.0yrs

Average Tenure

52.5yo

Average Age

Experienced Board: 1477's board of directors are considered experienced (5 years average tenure).